The Food and Drug Administration should approve the first messenger ribonucleic acid (mRNA) vaccine for influenza, the agency’s vaccine advisory panel said on June 18.
The Vaccines and Related Biological Products Advisory Committee in a unanimous vote advised the FDA to approve an mRNA flu shot from Moderna for adults aged 50 and older.
“The presented data do indicate efficacy against flu with no safety signals,” Dr. Hana El Sahly, a professor at the Baylor College of Medicine and committee member who worked on a trial for Moderna’s COVID-19 vaccine, said after the vote.
“I think that this particular platform adds exciting ways that we can actually move our vaccines to the future,” Dr. Hayley Gans, a Stanford Medicine Children’s Health pediatrics professor and fellow committee member, added….